MAPT and early-onset autosomal dominant Alzheimer disease: In streptozotocin-induced high-glucose APP/PS1/Tau triple transgenic (3×Tg-AD) mice, SGD also decreased the expression of NLRP1, NLRP3, Aβ, and Tau in the hippocampus and cortex, and improved working and spatial memory in the Y-maze and Morris water maze, thus demonstrating the potential of SGD in treating Alzheimer’s disease by alleviating neuroinflammation.